Eli Lilly’s AI Chief Thomas Fuchs Joins GeneDx Board Amid Genomic Testing Expansion

Thomas Fuchs, Chief AI Officer at pharmaceutical giant Eli Lilly (LLY), has been appointed to the board of GeneDx (WGS), a genomic testing company specializing in rare disease diagnostics. The MOVE signals growing convergence between artificial intelligence and precision medicine.

Fuchs brings DEEP expertise in deploying machine learning across healthcare applications, having led AI initiatives at Eli Lilly spanning drug discovery, clinical trials, and manufacturing. His prior roles include establishing the first AI chair at Mount Sinai Hospital and research positions at NASA’s Jet Propulsion Laboratory and Caltech.

GeneDx recently launched an AI-powered genetic analysis tool, leveraging what it claims is one of the world’s largest rare disease datasets. "Dr. Fuchs’ experience scaling AI infrastructure for diagnostic medicine is invaluable," the company stated regarding the appointment.